International Journal of Drug Delivery Technology
Volume 14, Issue 3

Teriflunomide Transdermal Cream: In-vitro And In-vivo Evaluation for the Treatment of Rheumatoid Arthritis

Venkata Nookaraju Sreedharala1*, Pavan Kumar Chintamaneni2

Department of Pharmaceutics, GITAM School of Pharmacy, GITAM deemed to be University, Hyderabad, Telangana, India. 

Received: 20th February, 2024; Revised: 27th March, 2024; Accepted: 15th August, 2024; Available Online: 25th September, 2024 

ABSTRACT

Rheumatoid Arthritis (RA) is an incurable long-term disease that requires continuous safe treatment. Currently, many anti- inflammatory agents and steroids are used to manage the diseases and are associated with a variety of side effects. There is a great need for a formulation that addresses the root cause of the disease and can be used for prolonged periods without any side effects. Hence, an attempt was made to develop a formulation of an alternative to steroid formulations that can be used for prolonged periods without/minimal side effects, i.e., teriflunomide topical dosage form. Teriflunomide tablet was approved for multiple sclerosis. It is the primary metabolite of leflunomide which is approved to treat RA. When leflunomide is administered orally converts to teriflunomide to elicit its action as such, leflunomide has no anti-rheumatoid effect. Both leflunomide and teriflunomide have different GIT side effects such as diarrhea, nausea, and hepatotoxicity on oral administration. To avoid these oral side effects of leflunomide and teriflunomide and to improve RA treatment compliance, teriflunomide was formulated as a topical cream. The developed topical cream is designed to be applied at night on the affected joints. It is intended to release the drug during the night, provide higher localized concentrations of the drug in the synovial joint and reduce GI and systemic side effects improving treatment compliance.

Keywords: Teriflunomide, Rheumatoid arthritis, Topical cream, Synovial joint, Drug targeting. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.52

How to cite this article: Sreedharala VN, Chintamaneni PK. Teriflunomide Transdermal Cream: In-vitro And In-vivo Evaluation

for the Treatment of Rheumatoid Arthritis. International Journal of Drug Delivery Technology. 2024;14(3):1615-1622.

REFERENCES

  1. Wasserman AM. Diagnosis and management of rheumatoid arthritis. American family physician. 2011;84(11):1245-1252.
  2. Hussain Manik Z, George J, Sockalingam S. Ultrasound Assessment of Synovial Thick ness of Some of the Metacarpophalangeal Joints of Hand in Rheumatoid Arthritis Patients and the Normal Population. Scientifica (Cairo) 2016; 5609132. doi: 10.1155/2016/5609132.
  3. Birch JT, Bhattacharya S. Emerging trends in diagnosis and treatment of rheumatoid Primary Care: Clinics in Office Practice. 2010;37(4):779-792.
  4. Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current therapeutic options in the treatment of rheumatoid arthritis. Journal of clinical medicine. 2019 Jun 28;8(7):938. https://doi. org/10.3390/jcm8070938
  5. Araki Y, Mimura T. The mechanisms underlying chronic inflammation in rheumatoid arthritis from the perspective of the epigenetic landscape. Journal of immunology research. 2016;2016(1):6290682. doi: 1155/2016/6290682.
  6. Laval X, Delarge J, Somers F, Tullio PD, Henrotin Y, Pirotte B, Dogne Recent advances in inducible cyclooxygenase (COX-2) inhibition. Current medicinal chemistry. 2000;7(10):1041-1062. doi: 10.2174/0929867003374417.
  7. Bost J, Maroon A, Maroon J. Natural anti-inflammatory agents for pain Surgical neurology international. 2010;1:80. doi: 10.4103/2152-7806.73804.
  8. Bariguian Revel F, Fayet M, Hagen Topical diclofenac, an efficacious treatment for osteoarthritis: a narrative review. Rheumatology and therapy. 2020;7(2):217-236. doi: 10.1007/ s40744-020-00196-6.
  9. Counsil of Europe. European Pharmacopoeia. 10th ed. Counsil of Europe; Strasbourg, France: 2019.
  10. Derry S, Moore RA, Gaskell H, McIntyre M, Wiffen PJ. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane database of systematic 2015(6):30. doi:10.1002/14651858.CD007402.pub3.
  11. Dave Mittal B, Dave Urmi M, Savajiyani Dixit Clinical efficacy of topical nanoemulsion diclofenac gel versus combination of nanoemulsion diclofenac with methyl salicylate in osteoarthritis of knee. J. Orthop. Trauma Surg. Relat. Res. 2017;12(3).
  12. Fonseca LJ, Nunes-Souza V, Goulart MO, Rabelo Oxidative stress in rheumatoid arthritis: What the future might hold regarding novel biomarkers and add‐on therapies. Oxidative medicine and cellular longevity. 2019;2019(1):7536805. https:// doi.org/10.1155/2019/7536805
  13. Van Vugt RM, Rijken PJ, Rietveld AG, Van Vugt AC, Dijkmans BA. Antioxidant intervention in rheumatoid arthritis: results of an open pilot Clinical rheumatology. 2008;27:771-775. doi: 10.1007/s10067-008-0848-6.
  14. Mahajan A, Tandon VR. Antioxidants and rheumatoid arthritis. Journal of Indian Rheumatology 2004;12:139-142.
  15. Gouda R, Baishya H, Qing Z. Application of mathematical models in drug release kinetics of carbidopa and levodopa ER tablets. Journal of Developing Drugs. 2017;6(02):1-8. doi: 4172/2329-6631.1000171.
  16. Ramteke KH, Dighe PA, Kharat AR, Patil Kant’s biological conception of history. Scholars Academic Journal of Pharmacy. 2014;3:388-396.
  17. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic International journal of pharmaceutics. 1983;15(1):25-35. https:// doi.org/10.1016/0378-5173(83)90064-9
  18. Costa P, Lobo Modeling and comparison of dissolution profiles. European journal of pharmaceutical sciences. 2001;13(2):123-133. https://doi.org/10.1016/S0928-0987(01)00095-1
  19. Bruschi Mathematical models of drug release. Strategies to Modify the Drug Release from Pharmaceutical Systems. Elsevier Ltd; 2015:63–86.
  20. Hussein WA, Zamil ST, Hussain MA, Kadhim Formulation Design and Evaluation of Hydrocortisone Gel for Topical Use. International Journal of Drug Delivery Technology. 2022;12(3):1162-1165. DOI: 10.25258/ijddt.12.3.39
  21. Ghurghure SM, Phatak AA. Formulation and Evaluation of Punica granatum L Seed Oil-loaded Cosmetic Cream: Its In-vitro Antioxidant Activity. International Journal of Pharmaceutical Quality Assurance. 2023;14(2):289-293. DOI: 10.25258/ 14.2.08
  22. Laware SG, Shirole NL. Formulation and Development of Polyherbal Ointment containing Clerodendrum serratum, Solanum xanthocarpum, and Nyctanthes arbortristis Extracts and Assessment of Anti-inflammatory Activity in Carrageenan-Induced Paw Edema Model. International Journal of Pharmaceutical Quality Assurance. 2023;14(3):523-528. DOI: 10.25258/ijpqa.14.3.10
  23. Jaber SA, Sulaiman HT, Rajab Preparation, Characterization and In-Vitro Diffusion Study of Different Topical Flurbiprofen Semisolids. International Journal of Drug Delivery Technology. 2020; 10(1):81-87. DOI: 10.25258/ijddt.10.1.12